Figure 1 presents the main effects of GLP1, GIP and glucagon in different body organs
Dealing with the standard titration schedule The standard semaglutide titration follows a step-up protocol designed to minimize gastrointestinal side effects
The pattern of side effects in long-term use shows that gastrointestinal symptoms are most prominent during the first 6 months, particularly during dose escalation
Even at low doses, these medications carry risks including pancreatitis (requiring discontinuation if suspected), gallbladder disease, and rare but serious adverse events such as medullary thyroid carcinoma (boxed warning
Patients were randomized 1:1 to receive subcutaneous semaglutide 2.4 mg once weekly or placebo as an adjunct to standard-of-care therapy for CVD, such as cholesterol-modifying medications, antiplatelet therapies and antihypertensive agents
Understanding the evidence base, bioavailability limitations, and genetic factors influencing liver metabolism can support more informed decisions and meaningful conversations with qualified healthcare providers